Arvinas reports delay for Pfizer-partnered protein degradation program
Arvinas’ stock plunged about 17% on Monday after the company revealed another delay for its Pfizer-partnered protein degrader in combination with Ibrance, also known as palbociclib.
A recent analysis of an ongoing Phase Ib study in first-line metastatic breast cancer patients showed an “increase in palbociclib exposure” that CEO John Houston told Endpoints News is “probably just outside the range of what we’d expect to be normal.” That led the companies to propose a modification to the planned Phase III VERITAC-3 study, which will likely set the launch back to the second half of this year, Arvinas announced in an SEC filing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.